Bayer Reports Results of Eliapixant (BAY1817080) in P-IIb Study for the Treatment of Refractory Chronic Cough
- The P-IIb clinical trial involves evaluating the efficacy and safety of eliapixant (25/75/150mg- PO- bid) vs PBO in 300 patients with refractory chronic cough for 12wks.
- The trial met its 1EPs that showed an improvement in 24hrs. cough counts @12wks. of treatment. The results showed a favorable safety and tolerability profile of the therapy
- Eliapixant is a potent and selective P2X3 receptor antagonist. The therapy is currently being evaluated in P-II clinical trials for the treatment of endometriosis- overactive bladder- and neuropathic pain
to | Ref: Bayer | Image: Business Standard
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at firstname.lastname@example.org